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Abstract
Background
The Phase 2b double-blinded, randomized Phambili/HVTN 503 trial evaluated safety and
efficacy of the MRK Ad5 gag/pol/nef subtype B HIV-1 preventive vaccine vs placebo in sex-
ually active HIV-1 seronegative participants in South Africa. Enrollment and vaccinations
stopped and participants were unblinded but continued follow-up when the Step study eval-
uating the same vaccine in the Americas, Caribbean, and Australia was unblinded for non-
efficacy. Final Phambili analyses found more HIV-1 infections amongst vaccine than pla-
cebo recipients, impelling the HVTN 503-S recall study.
Methods
HVTN 503-S sought to enroll all 695 HIV-1 uninfected Phambili participants, provide HIV
testing, risk reduction counseling, physical examination, risk behavior assessment and
treatment assignment recall. After adding HVTN 503-S data, HIV-1 infection hazard ratios
(HR vaccine vs. placebo) were estimated by Cox models.
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Results
Of the 695 eligible, 465 (67%) enrolled with 230 from the vaccine group and 235 from the
placebo group. 38% of the 184 Phambili dropouts were enrolled. Enrollment did not differ
by treatment group, gender, or baseline HSV-2. With the additional 1286 person years of
503-S follow-up, the estimated HR over Phambili and HVTN 503-S follow-up was 1.52
(95% CI 1.08–2.15, p = 0.02, 82 vaccine/54 placebo infections). The HR was significant
for men (HR = 2.75, 95% CI 1.49, 5.06, p = 0.001) but not for women (HR = 1.12, 95% CI
0.73, 1.72, p = 0.62).
Conclusion
The additional follow-up from HVTN 503-S supported the Phambili finding of increased HIV-
1 acquisition among vaccinated men and strengthened the evidence of lack of vaccine
effect among women.
Trial Registration
clinicaltrials.gov NCT00413725
SA National Health Research Database DOH-27-0207-1539
Introduction
Developing a safe and effective vaccine against HIV-1 acquisition remains a public health pri-
ority and a scientific challenge three decades after the discovery of the HIV-1 virus and the
launch of the first HIV-1 vaccine clinical trial. Of the six large-scale HIV-1 vaccine efficacy tri-
als conducted in humans to date, only the RV144 Thai trial testing a canarypox vectored prime
(ALVAC-HIV)/ALVAC + gp120 boost vaccine regimen has shown a modest prevention effect
(31%) [1]. Two earlier trials of a recombinant bivalent gp120 vaccine, one in a Thai injecting
drug cohort and the other in a cohort primarily comprising men who have sex with men
(MSM) in the Americas and the Netherlands, and a recent trial with a DNA prime recombi-
nant adenovirus serotype-5 (rAd5) boost vaccine regimen among MSM in the United States
showed no efficacy [2–4]. Two other trials [5, 6] of a rAd5-vectored vaccine expressing HIV-1
internal proteins Gag, Pol and Nef also showed no vaccine efficacy and raised the possibility of
increased HIV-1 acquisition in the vaccine group despite clinical safety and immunogenicity
demonstrated in multiple phase1/2 studies [7–15].
The Step study tested the MRK rAd5 vectored polyvalent HIV-1 gag/pol/nef subtype B vac-
cine in a cohort consisting primarily of MSM and at-risk women in the Americas, Caribbean
and Australia, where the circulating HIV-1 is of subtype B. In September 2007, the first interim
efficacy analysis concluded that the trial met the pre-specified criteria for futility, thus vaccina-
tions were halted, follow-up continued, and participants were informed of their treatment
assignments. Subgroup analyses among Ad5 seropositive and/or uncircumcised men at that
time showed an increased susceptibility to HIV-1 acquisition in those who received vaccine vs.
placebo (based on interaction tests) [5]; analyses by Ad5 serostatus subgroups were pre-speci-
fied however the analyses of Ad5 status and circumcision subgroups were not. At the end of
four years of follow-up, for all participants the vaccine:placebo hazard ratio [HR] for HIV-1
infection was 1.40 (95% CI 1.03–1.92; p = 0.03) [16]. The vaccine-induced enhanced risk of
HIV-1 acquisition seen in the Ad5 seropositive and/or uncircumcised men was more evident
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in the first 18 months of follow-up and appeared to wane over time, whereas for circumcised,
Ad5 seronegative men, the vaccine:placebo HR increased over time from 0.38 (95% CI 0.16–
0.90) in the first 18 months to 2.18 (95% CI (0.97–4.92) after 18 months of follow-up. There
were too few infections among women to assess vaccine efficacy.
The second Phase 2b trial of the MRK rAd5 vaccine, HVTN 503 or Phambili [6, 17], was
undertaken in South Africa, where clade C is the predominant HIV-1 subtype, in a principally
heterosexual population. Enrollment and vaccinations were halted in September 2007 when
the Step study met the non-efficacy criteria. By that time, Phambili had enrolled 800 HIV non-
infected participants aged 18–35 years (median 22), 55% of whom were men. Participants were
unblinded to their treatment assignments and followed for 42 months. The initial Phambili
analysis based on a median of 25 months of follow-up reported a higher number of HIV-1
infections in the vaccine vs placebo groups but no significant difference overall or by gender
[17]. Over the entire Phambili follow-up period (with median follow-up of 42 months), a sig-
nificantly higher rate of HIV-1 infections was seen in the vaccine group than in the placebo
group, with the difference stronger for men than for women [6]. This difference could not be
explained by number of vaccinations received, dropout or self-reported risk behaviors.
Although there was no difference in retention between vaccine and placebo groups over the
42 months of follow-up in Phambili, the early trial unblinding of participants and staff and the
potential of imbalanced undetected HIV-1 infections among participants who dropped-out
may have affected results. To better assess the HIV acquisition risk, the study investigators
undertook a follow-up study, HVTN 503-S, to recall all HIV-1 uninfected participants for an
additional HIV test. This report describes the success of this recall effort and provides estimates
of the vaccine effect on HIV-1 acquisition that include HIV infection data from the HVTN
503-S recall study.
Methods
Study Design
HVTN 503-S was designed to enroll the 695 Phambili participants who were HIV uninfected
and known to be alive at the end of their Phambili follow-up for additional HIV testing. Partic-
ipants were from all 5 South African Phambili sites (Soweto, Cape Town, Klerksdorp-Orkney-
Stilfontein-Hartbeestfontein [KOSH], eThekwini, and MEDUNSA). The primary objectives
were to expand HIV diagnostic testing coverage and to expand information on behavioral risk.
After providing informed consent in which participants were informed about the Phambili
study results, participants received a physical examination, which for men included circumci-
sion status assessment; received HIV counseling and testing; received HIV risk reduction
counseling; and were assessed for their treatment assignment recall. Staff also administered a
short behavioral risk assessment that asked about change in sexual practices (frequency of sex,
number of partners, and condom use) between the participant’s last year in the Phambili trial
compared to the following year; response categories were no change, increased or decreased.
Participants who tested HIV positive had an additional visit to confirm the result. A concern
was that male circumcision status may not have been adequately assessed on Phambili since
39% of reports of circumcision at enrollment were based on self-report and complete and par-
tial circumcisions were not distinguished. For HVTN 503-S, the physical examination required
observation of circumcision status unless the participant declined, and staff were specifically
trained to distinguish partial from complete circumcisions.
Because vaccine recipients may have had vaccine-induced seropositivity, HIV testing for
vaccinees was performed by the National Institute for Communicable Diseases (NICD, Johan-
nesburg, South Africa) following the testing algorithm used in Phambili. For placebo recipients,
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the site or local lab performed testing following their site guidelines and referred additional
specimens to NICD for RNA PCR testing for any participants who had a possible recent HIV-
1 exposure or evidence of acute infection.
Each site had a six month enrollment window from protocol activation. Sites used various
methods to contact Phambili participants which included text messaging and phone calls to
the participant’s last known phone number; home visits by field workers, Community Advisory
Board (CAB) and study retention officers; advertising in local newspapers and on radio; and
use of loud speakers from vehicles driving in areas where Phambili participants were initially
recruited.
The study was registered with the Food and Drug Administration in the USA as an amend-
ment to the Phambili investigational new drug application and was approved by the ethical
review committees and the institutional review boards of the University of the Witwatersrand,
University of Cape Town, University of Limpopo and the University of Kwazulu-Natal. Partici-
pants provided written informed consent in English or their local language.
Statistical Analysis
All analyses were modified intention-to-treat (MITT). The MITT population included all vac-
cinated participants apart from those diagnosed as infected with HIV-1 on the day of first vac-
cination. Differences between categorical variables were tested with Chi-square tests or Fisher’s
exact tests for 2 X 2 tables. Multivariable logistic regression models were used to assess predic-
tors of enrollment in HVTN 503-S, including Phambili treatment group, gender, age, HSV-2
serostatus at enrollment in Phambili, circumcision status at the end of Phambili follow-up
(men), early discontinuation of Phambili follow-up and HIV risk behaviors reported at their
last Phambili visit (multiple partners, unprotected sex, drinking or drug use with sex, no main
partner, heavy drinking or dagga [marijuana] use). Kaplan-Meier cumulative incidence plots
of time to HIV-1 infection by treatment groups for the combined Phambili and HVTN 503-S
follow-up times are provided for the entire cohort and by gender subgroups, with log-rank
tests used to determine statistical significance. Cox proportional hazards models were used to
estimate the HR for HIV-1 infection due to vaccination (vaccine:placebo), overall and within
subgroups. Time-dependent Cox models were used when circumcision was included in the
model as many men were circumcised while on study. Differences in HRs between subgroups
were assessed with Wald tests for the vaccine by subgroup interaction. Time to HIV-1 infection
for participants infected while on Phambili was defined as the time from first Phambili study
injection to the midpoint between the last plasma HIV-1 RNA negative and first RNA positive
test; for HIV-1 infections diagnosed at the HVTN 503-S visit, the midpoint was determined
from the time of the last plasma HIV-1 RNA negative test in Phambili. For uninfected partici-
pants, the censoring time was defined as the time from first study injection to the HVTN 503-S
HIV test or last Phambili test for those not enrolled in HVTN 503-S. Circumcision status was
based on the HVTN 503-S physical assessment; partial circumcisions were considered as uncir-
cumcised in the analysis. For men refusing the HVTN 503-S examination or who were not
enrolled in HVTN 503-S, their Phambili circumcision assessment was used. Results presented
for the Phambili follow-up period include the additional follow-up and assessment data for all
HVTN 503-S participants and updated baseline HSV-2 data for 2 participants. All p-values are
2-sided. SAS and R were used to run all analyses.
Results
HVTN 503-S began enrolling participants in June 2013 and follow-up was completed in Janu-
ary 2014. Of the 695 participants targeted for enrollment in HVTN 503-S, 57.3% were men,
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48.2% had received vaccine, and 26.5% had discontinued follow-up on Phambili early. 465
(66.9%) of the 695 were enrolled, with a significant difference in enrollment percentages
between study sites (p<0.001) and by circumcision status at the end of Phambili follow-up
(p = 0.045), but not by Phambili treatment groups, gender, Ad5 serostatus, age, or by baseline
HSV-2 status (table 1). Enrollment rates were higher for those who completed Phambili fol-
low-up than those who discontinued early overall and within gender subgroups (p-
values< 0.001). Among the 184 participants who discontinued Phambili follow-up early, 70
(38.0%) were enrolled in HVTN 503-S, with no significant difference by treatment group.
More vaccinees were enrolled than placebo recipients at Soweto (p = 0.045) and Cape Town
(p = 0.03); no significant differences were seen in enrollment rates at other sites. Multivariable
logistic regression models identified study site (p<0.001) and discontinuation of Phambili
Table 1. HVTN 503-S contact disposition for eligible Phambili participants (N = 695).
All Vaccined Placebod
Characteristic # Enrolled/ # eligible
(%)
p-value for subgroup
comparison
# Enrolled/# eligible
(%)
# Enrolled/# eligible
(%)
Overall 465/695 (66.9%) 230/335 (68.7%) 235/360 (65.3%)
Sex 0.25
Men 259/398 (65.1%) 130/193 (67.4%) 129/205 (62.9%)
Women 206/297 (69.4%) 100/142 (70.4%) 106/155 (68.4%)
Circumcision status at end of Phambili
follow-upa
0.045
Circumcised men 176/252 (69.8%) 94/124 (75.8%) 82/128 (64.1%)
Uncircumcised men 83/139 (59.7%) 36/66 (54.6%) 47/73 (64.4%)
Ad5 serostatus 0.36
Ad5 seropositive 370/560 (66.1%) 187/271 (69.0%) 183/289 (63.3%)
Ad5 seronegative 95/135 (70.4%) 43/64 (67.2%) 52/71 (73.2%)
Age 1.0
Age  25 years 335/501 (66.9%) 163/243 (67.1%) 172/258 (66.7%)
Age > 25 years 130/194 (67.0%) 67/92 (72.8%) 63/102 (61.8%)
Study site <0.001
Soweto 223/266 (83.8%) 111/125 (88.8%) 112/141 (79.4%)
Cape Town 75/139 (54.0%) 43/67 (64.2%) 32/72 (44.4%)
KOSH 106/204 (52.0%) 48/102 (47.1%) 58/102 (56.9%)
eTwekwini 25/40 (62.5%) 10/18 (55.6%) 15/22 (68.2%)
Medunsa 36/46 (78.3%) 18/23 (78.3%) 18/23 (78.3%)
Phambili follow-up status <0.001 b
Completed 395/511 (77.3%) 194/249 (77.9%) 201/262 (76.7%)
Discontinued early 70/184 (38.0%) 36/86 (41.9%) 34/98 (34.7%)
Baseline HSV-2 statusc 0.13
Seronegative 338/492 (68.7%) 165/235 (70.2%) 173/257 (67.3%)
Seropositive 126/201 (62.7%) 64/99 (64.6%) 62/102 (60.8%)
a 7 men eligible for HVTN 503-S did not have a circumcision assessment after enrollment in Phambili.
bDifferences in enrollment between those who completed Phambili follow-up and those who discontinued early were also statistically signiﬁcant within
gender subgroups (all p-values < 0.001).
c Two participants were missing HSV-2 data at enrollment in Phambili.
d Differences in enrollment between vaccine and placebo groups overall or within subgroups were not statistically signiﬁcant, except for Soweto
(p = 0.045) and Cape Town (p = 0.03); the p-value for circumcised men was 0.054.
doi:10.1371/journal.pone.0137666.t001
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follow-up (p<0.001) as predictors of enrollment, but not demographics or HIV risk behaviors.
Reasons for non-enrollment (n = 230) were: 97 unable to be contacted, 77 relocated away from
a study site, 36 unable to be scheduled for a visit or no show for their scheduled visit, 15 not
interested, 3 died from unknown causes after their last Phambili visit, and for 2 the enrollment
period ended prior to making contact (S1 Fig). There were no differences in reasons by treat-
ment arm or gender (data not shown). The median time between last Phambili and the HVTN
503-S visit was 33 months (IQR 31, 35). The extended follow-up added 1,286 person-years of
follow-up to the 2,268 person-years observed during Phambili.
HVTN 503-S HIV testing identified 36 new HIV-1 infections, 19 in the vaccine group and
17 in the placebo group (table 2). In the combined Phambili and HVTN 503-S follow-up peri-
ods, significantly more HIV-1 infections were detected amongst vaccinees (n = 82) as com-
pared to placebo (n = 54); the annualized HIV-1 incidence rate was 4.7% (95% CI 3.7%-5.8%)
for vaccinees and 3.0% (95% CI 2.3%-3.9%) for placebo recipients (p = 0.01, Fig 1, table 2). The
vaccine:placebo HR adjusted for HSV-2 status at the time of enrollment in Phambili was 1.52
(95% CI: 1.08, 2.15) in the combined Phambili and HVTN 503-S data, compared to 1.70 (95%
CI: 1.13–2.55, p = 0.01) in Phambili alone(table 3); baseline HSV-2 status was a significant pre-
dictor of HIV infection thus the Cox models always adjust for this variable.
Table 2. Incident HIV-1 infections detected during Phambili and Phambili + HVTN 503-S follow-up periods.
Overall Vaccine Placebo
Person-
years
N #
infections
Annualized HIV-1
incidence rate
(95%
CI)
N #
infections
Annualized HIV-1
incidence rate
(95% CI)
Phambili follow-up
All 2269 400 63 5.6% (4.3,
7.2)
400 37 3.2% (2.3, 4.5)
Men 1269 222 28 4.4% (2.9,
6.4)
219 11 1.7% (0.9, 3.1)
Women 1000 178 35 7.2% (5.0,
10.0)
181 26 5.1% (3.3, 7.4)
Phambili + 503-S follow-up
All 3555 400 82 4.7% (3.7,
5.8)
400 54 3.0% (2.3, 3.9)
Men 1998 222 39 3.9% (2.8,
5.3)
219 14 1.4% (0.8, 2.3)
Women 1557 178 43 5.6% (4.1,
7.6)
181 40 5.0% (3.6, 6.9)
Completed Phambili FU 2968 312 75 5.1% (4.0,
6.4)
299 50 3.4% (2.5, 4.4)
Discontinued Phambili
FU
586 88 7 2.5% (1.0,
5.1)
101 4 1.3% (0.4, 3.4)
Men completed
Phambili FU
1605 167 33 4.0% (2.8,
5.7)
150 14 1.8% (1.0, 3.0)
Women completed
Phambili FU
1363 145 42 6.4% (4.6,
8.6)
149 36 5.1% (3.6, 7.1)
Men discontinued
Phambili FU
393 55 6 3.4% (1.2,
7.3)
69 0 0.0% 0.0, 1.7)
Women discontinued
Phambili FU
193 33 1 1.0% (0.0,
5.4)
32 4 4.5% (1.2,11.4)
CI = conﬁdence interval. HIV-1 = human immunodeﬁciency virus 1.
doi:10.1371/journal.pone.0137666.t002
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Fig 1. Cumulative HIV-1 incidence curves for vaccine and placebo groups for Phambili and Phambili + HVTN 503-S follow-up; Phambili + HVTN
503-S curves are based on all MITT Phambili participants (n = 800) with updated HIV-1 status for the subset of participants enrolled in HVTN 503-S
(n = 465).
doi:10.1371/journal.pone.0137666.g001
Table 3. Risk of HIV-1 infection (vaccine vs placebo), adjusted for herpes simplex virus 2 status at Phambili enrollment, within subgroups.
Phambili follow-up Phambili + 503-S follow-up
HR (95% CI) p-value HR (95% CI) p-value
Overall 1.70 (1.14, 2.56) 0.01 1.52 (1.08, 2.15) 0.02
Sex 0.19 a 0.02 a
Women 1.42 (0.85, 2.35) 0.18 1.12 (0.73, 1.72) 0.62
Men 2.46 (1.22, 4.93) 0.01 2.75 (1.49, 5.06) 0.001
Circumcision status 0.48 a 0.43a
Men circumcised at baseline or on study 3.25 (1.06, 9.98) 0.04 3.69 (1.38, 9.89) 0.01
Uncircumcised men 1.99 (0.81, 4.90) .14 2.27 (1.03, 5.02) 0.04
Ad5 serostatus 0.98 a 0.75 a
Ad5 seropositive 1.70 (1.08, 2.67) 0.02 1.57 (1.07, 2.31) 0.02
Ad5 seronegative 1.70 (0.66, 4.40) 0.27 1.37 (0.64, 2.94) 0.41
Age 0.95 a 0.96 a
Age  25 years 1.72 (1.04, 2.84) 0.03 1.51 (0.99, 2.30) 0.055
Age > 25 years 1.66 (0.83, 3.32) 0.15 1.54 (0.85, 2.80) 0.15
Study site 0.50 a 0.50 a
Soweto 2.39 (1.18, 4.83) 0.02 2.00 (1.10, 3.64) 0.02
Cape Town 1.86 (0.84, 4.14) 0.13 1.78 (0.86, 3.68) 0.12
KOSH 0.87 (0.33, 2.25) 0.77 1.03 (0.51, 2.08) 0.94
eThekwini 1.91 (0.62, 5.94) 0.26 1.83 (0.68, 4.91) 0.23
Medunsa 1.04 (0.21, 5.21) 0.96 0.73 (0.16, 3.27) 0.68
HR = hazard ratio (vaccine vs placebo), adjusted for baseline herpes simplex virus 2 status. Ad5 = adenovirus serotype 5.
a p-value for test of interaction for subgroup and treatment group
doi:10.1371/journal.pone.0137666.t003
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With the additional HVTN 503-S follow-up, the vaccine:placebo HRs were significantly dif-
ferent for men and women (interaction p = 0.02, table 3). The effect on HIV-1 acquisition by
vaccination status was more pronounced in men [HR = 2.75, 95% CI: (1.49, 5.06)], and less for
women [HR = 1.12, 95% CI: (0.73, 1.72)], Fig 2. There was no evidence that the HR varied by
baseline Ad5 status, age, study site or, in men, by time-dependent circumcision status (interac-
tion p-values 0.42, table 3). Sites promoted male circumcision as an HIV prevention mea-
sure. Although men may have been at increased risk of HIV infection in the weeks following
circumcision, there were few HIV-1 infections diagnosed within 3 months following circumci-
sion. The 14 men circumcised at enrollment who later acquired HIV had been circumcised a
minimum of 8 months prior to enrollment into Phambili. Among the 11 men who were cir-
cumcised after enrollment and became HIV-1 infected, 7 had an HIV negative test at least 2
months after their circumcision and the other 4 were HIV seropositive at their first post-cir-
cumcision HIV test between 3–6 months post-circumcision (they had no HIV seronegative
test after circumcision).
Fig 2. Cumulative HIV-1 incidence curves for vaccine and placebo groups for Phambili and Phambili + HVTN 503-S follow-up by gender.
doi:10.1371/journal.pone.0137666.g002
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Of the 441 men enrolled in Phambili, 271 (61%) were categorized as completely circumcised
either at enrollment or during follow-up (up to and including final Phambili study visit), (table
4). For half of these men (134/271), circumcision status was based on visual exam; for the other
half, self-report was accepted (136/271); and 1 circumcised man was missing data on Phambili
assessment method. The remaining 170 men were categorized as uncircumcised, primarily
based on self-report (159, 94%); only 11 (6%) underwent visual exam of their circumcision sta-
tus at their final Phambili assessment.
259 of the 441 Phambili men (59%) enrolled in HVTN 503-S and 240 (92%) of these agreed
to undergo physical examination to verify their circumcision status (S2 Fig). Of those men
whose circumcision status was verified by physical examination in HVTN 503-S, 94% (225/
240) were found to have been correctly categorized in Phambili. The remaining 15 men (6%)
who underwent physical examination in HVTN 503-S were found to have had their circumci-
sion status mis-categorized in Phambili.
Table 4. Comparison for men of circumcision status from Phambili to HVTN 503-S assessment (N = 441).
Phambili
Assessment
Phambili
Assessment
Method
Total for Phambili 503-S Circumcision Assessment (physical examination) No 503-S Circumcision
Assessment
Circumcised at
Phambili
enrollment
Circumcised
during Phambili
follow-up
Circumcised
between end of
Phambili follow-
up and 503-S visit
Uncircumcised
Circumcised at
Phambili
enrollment
129 62 0 0 4a 1 62
Physical
examination
79 39 0 0 2 b 0 38
Self-report 50 23 0 0 2 b 1 24
Circumcised during
Phambili follow-up
142 0 93c 0 3d 12 34
Physical
examination
55 0 41 0 3 b 1 10
Self-report 86 0 51 0 0 b 11 24
Uncircumcised
throughout
Phambili follow-up
162 2 6 10 60 6 78
Physical
examination
9 0 0 1 2 0 6
Self-report 153 2 b 6 b 9 58 6 72
Uncircumcised at
Phambili
enrollment but no
follow-up
circumcision
assessment
8 0 0 0 0 0 8
Physical
examination
2 0 0 0 0 0 2
Self-report 6 0 0 0 0 0 6
Total 441 64 99 10 67 19 182
a All had partial circumcisions.
b Participants with discordant circumcision status data between Phambili and 503-S (i.e., Phambili assessment was incorrect): 6% (15/240)
c1 man circumcised during Phambili follow-up was missing data on Phambili assessment method.
d 2 of the 3 had partial circumcisions.
doi:10.1371/journal.pone.0137666.t004
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The majority (83%) of enrolled participants correctly recalled their treatment assignment,
with no difference in recall between treatment groups, HIV-infection status, or by gender. Those
who had discontinued Phambili follow-up early (n = 70) were less likely to correctly remember
their treatment assignment than those who completed follow-up (n = 394): 18.6% vs 8.4%.
Most participants reported no change in frequency of sex (75.4%), number of sexual part-
ners (79.7%) or condom use (78.8%) between the year before and year after their last Phambili
visit (table 5). There were no differences in these self-reported risk behaviors by Phambili treat-
ment group (table 5) or follow-up status (data not shown). Women were more likely than men
to report no change (table 5). Borderline differences between treatment groups were seen for
men with number of partners (p = 0.054), with placebo recipients more likely to report an
increase in number of partners (16.4%) than vaccinees (6.9%) and for women, placebo recipi-
ents more likely to report a decrease in condom use (17.0%) than vaccinees (6.1%) (p = 0.052).
Discussion
The additional data from the extended follow-up of participants in HVTN 503-S substantiated
the finding of increased HIV-1 acquisition among vaccinated Phambili men. The recall study
also strengthened the evidence of a lack of vaccine effect among women, where the high HIV-1
incidence seen in women implied sufficient power for this evaluation. Due to the uncertainty
in the timing of the infections diagnosed in HVTN 503-S (approximately 3 years between the
last seronegative test in Phambili and the seropositive test in HVTN 503-S), we cannot deter-
mine whether the increased risk of acquisition seen in men is sustained at the time of the
HVTN 503-S or whether most of the infections among vaccinated men occurred shortly after
their last Phambili visit. A biological mechanism to explain the increased risk associated with
the recombinant adenovirus 5 vectored polyvalent HIV-1 gag/pol/nef subtype B vaccine has
not been identified. Vaccination may have led to an increased number of activated Ad5-specific
T cells that then served as target cells for HIV-1 [18–21].
Another possible explanation is that vaccine-induced subclinical inflammation may have
contributed to the increased rate of HIV-1 infection in men. Vaccine-induced subclinical
Table 5. Change in self-reported risk behavior between one year before and one year after last Phambili visit.
All (N = 463) Vaccine
(N = 229)
Placebo
(N = 234)
Men
(N = 258)
Women
(N = 205)
N % N % N % p-value N % N % p-value
Frequency of sex 0.75 0.047
Decreased 50 10.8 27 11.8 23 9.8 35 13.6 15 7.3
No change 349 75.4 172 75.1 177 75.6 184 71.3 165 80.5
Increased 64 13.8 30 13.1 34 14.5 39 15.1 25 12.2
Number of partners 0.11 < 0.001
Decreased 55 11.9 27 11.8 28 12.0 42 16.3 13 6.4
No change 368 79.7 188 82.5 180 76.9 186 72.1 182 89.2
Increased 39 8.4 12 5.7 26 11.1 30 11.6 9 4.4
Condom use 0.37 0.005
Decreased 52 11.2 21 9.2 31 13.2 28 10.9 24 11.7
No change 365 78.8 184 80.3 181 77.4 194 75.2 171 83.4
Increased 46 9.9 24 10.5 22 9.4 36 14 10 4.9
One man who received placebo and one woman who received vaccine are missing risk behavior data and an additional female vaccinee is missing
change in number of partners.
doi:10.1371/journal.pone.0137666.t005
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inflammation may not have contributed to any additional risk of HIV-1 acquisition for women
in the trial given the high levels of genital inflammation already present in the general popula-
tion of South African women [22].
The HVTN 503-S finding of increased risk of HIV-1 acquisition among vaccinated men
supports the Step results. However, unlike Step, we did not see differences in HIV-1 risk due to
the vaccine among subgroups of circumcised and uncircumcised men or in those with vs. with-
out prior immunity to Ad5. This may be due to differences in study population: the Step cohort
consisted mainly of MSM in the Americas, Caribbean, and Australia whereas the Phambili
cohort consisted mainly of South African heterosexuals having vaginal sex and a higher pro-
portion of participants who were Ad5 seropositive at enrollment (81%).
While enrollment into HVTN 503-S was high, 33% of the targeted Phambili participants
did not enroll. This was mostly due to inability to contact participants, unsurprising given the
young study population and the long interval (almost 3 years) between last contact in Phambili
and the start of the recall study and the high rates of migration in some of the trial communi-
ties. Enrollment rates differed by site but not by the following significant predictors of HIV-1
acquisition in Phambili: treatment group, gender, or baseline HSV-2 status. Therefore the par-
ticipants enrolled in the recall study were well matched to those who did not enroll on the key
known risk factors in the Phambili study population. Nonetheless, the recall study was not able
to enroll a third of the eligible uninfected Phambili participants and it is possible that these par-
ticipants differed with respect to unmeasured risk factors from those who did enroll.
In addition to supporting the overall Phambili findings, the recall study has identified chal-
lenges in collecting circumcision data in a population where self-reported data may be unreli-
able and on-study circumcision rates are high. Our concerns regarding accuracy of the
circumcision status assessment in Phambili were warranted. In HVTN 503-S, 6% of men who
accepted a physical examination had discrepant circumcision status between Phambili and
HVTN 503-S due to inaccurate self-report and incorrect physical examination assessments.
This indicates that better training is needed in both of these areas including guidance on distin-
guishing partial circumcisions and the importance of verifying self-reporting uncircumcised
men by physical examination. Partial circumcisions were classified as uncircumcised in the risk
of acquisition analyses given data indicating that the presence of the inner foreskin fold may
increase the risk of HIV entry [23]. Among the 19 men who declined physical examination, 7
were from one site and represented half of the men enrolled by the site. During the conduct of
HVTN 503-S, the site identified that this was due in part to a staff member who was uncom-
fortable performing a genital exam. For future trials in this region in which male circumcision
status has the potential to affect the evaluation of the efficacy of the study intervention, we rec-
ommend that physical examinations be done by staff who are trained in determining circumci-
sion status and in communicating to participants the importance of a visual exam.
Consideration should also be given to repeat assessment of circumcision status if it is expected
to change throughout the trial for a substantial proportion of men.
The high proportion of correct recall of Phambili treatment assignment among HVTN
503-S participants, with no differences by treatment group or by gender, indicates that sites
were informing participants clearly of their treatment assignment and that the information was
well retained.
Finally, the HVTN 503-S recall study demonstrated the skill and dedication of site staff in
locating and enrolling a large proportion of Phambili participants almost 3 years after the end
of the Phambili study. Staff succeeded in enrolling 38% of participants who had dropped out of
Phambili several years before; this speaks to the commitment of the participants, community
advisory board members, and the site staff. Through their efforts, HVTN 503-S provided addi-
tional data that supported the results of the analysis of the Phambili primary objectives.
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